Singapore markets close in 4 hours 41 minutes

Mesa Laboratories, Inc. (MLAB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
91.28-0.39 (-0.43%)
At close: 04:00PM EDT
89.58 -1.70 (-1.86%)
After hours: 07:16PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close91.67
Open90.00
Bid91.13 x 100
Ask92.63 x 100
Day's range89.09 - 91.99
52-week range82.86 - 145.46
Volume35,556
Avg. volume38,692
Market cap492.369M
Beta (5Y monthly)0.85
PE ratio (TTM)N/A
EPS (TTM)-47.20
Earnings date01 Aug 2024 - 05 Aug 2024
Forward dividend & yield0.64 (0.70%)
Ex-dividend date31 May 2024
1y target est125.00
  • Simply Wall St.

    Mesa Laboratories Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

    Mesa Laboratories ( NASDAQ:MLAB ) Full Year 2024 Results Key Financial Results Revenue: US$216.2m (down 1.3% from FY...

  • GlobeNewswire

    Mesa Labs Announces Fourth Quarter and Full Fiscal Year 2024 Results

    LAKEWOOD, Colo., June 05, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its fourth fiscal quarter (“4Q24”) and fiscal year (“FY24”) ended March 31, 2024 (amounts in thousands). Fourth quarter FY24 compared to fourth quarter FY23: Revenues increased 6% and increased 10.2% vs 3Q24Non-GAAP core organic revenues1 decreased 3.5%Operating (loss) was

  • GlobeNewswire

    Mesa Laboratories, Inc. Revises Earnings Announcement date for Unaudited Fourth Quarter and Full Fiscal Year 2024 Results

    LAKEWOOD, Colo., May 31, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (“Mesa”) (NASDAQ:MLAB) will not issue its 2024 financial results for the fourth quarter and the fiscal year ending March 31, 2024 today as previously communicated. The earnings announcement has been delayed as we work to finalize our year end audit which is focused on finalizing the calculations and technical accounting for previously-announced impairments of long-lived assets and goodwill related to our Clinical Genomics